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DOI: 10.1039/c2md20018jSignal Transducer and Activator of Transcription 3 (STAT3) is a latent cytoplasmic protein
overexpressed in various cancer cell lines. STAT3 participates in oncogenesis by stimulating cell
proliferation and preventing apoptosis and it has been proven as a suitable target for anticancer
therapy. In order to identify direct STAT3 inhibitors, we performed a binding assay on several
previously synthesized 1,2,5-oxadiazole derivatives. Among them, compound MD77, N-[4-(4-
chlorophenyl)-1,2,5-oxadiazol-3-yl]-4-(trifluoromethyl)benzamide, showed a good ability to bind the
STAT3–SH2 domain in a dose-dependent manner (IC50 ¼ 17.7 mM). Computational studies were
carried out to investigate its binding mode. Moreover, compound MD77 showed a significant anti-
proliferative activity versus several tumor cell lines. On these bases, compound MD77 was selected as
a lead for the future development of direct STAT3 inhibitors.Introduction
Signal Transducers and Activators of Transcription (STATs) are
a family of cytoplasmic proteins which have two critical roles: to
transduce signals through the cytoplasm and to act as tran-
scription factors in the nucleus. Seven STAT family members,
encoded by distinct genes, were identified, namely STAT1 to
STAT4, STAT5a, STAT5b and STAT6.1They are constituted by
several structurally and functionally conserved domains: the
N-terminal coiled-coil (involved in STAT dimer–dimer interac-
tions), the DNA binding domain (responsible for complex
formation between STAT proteins and DNA), the Src homology
2 (SH2) (a linker region required for the recruitment of STAT
monomers through reciprocal pTyr–SH2 domain interaction),
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cascade involves the phosphorylation of a specific tyrosine
residue, which allows the protein dimerization and translocation
to the nucleus where STATs are able to modulate gene tran-
scription through a direct binding to DNA.
In particular, STAT3 is constitutively activated in a wide
variety of human solid and blood tumors3,4 as a result of
a deregulation of cytokine receptors, growth factors and Janus
kinases (JAK) activity.5,6 The inhibition of STAT3 signaling
leads to growth arrest and apoptosis of various cancer cell lines,
suppresses cancer cell survival, and induces tumor regression,7–9
having no effects in normal cells.10 For these reasons, STAT3 can
be considered a promising target for anticancer therapy. STAT3
signaling can be inhibited through direct interaction of molecules
with the protein or by indirect inhibition of the upstream tyrosine
kinases or blockage of other factors involved in the activation.11
Since the indirect approach is endowed with a poorly specific
mechanism of action that could cause important adverse effects,This journal is ª The Royal Society of Chemistry 2012
the challenge is the discovery of new selective and direct STAT3
inhibitors.
In a previous paper,12 we studied, as potential STAT3 inhibi-
tors, three series of 1,2,5-oxadiazoles, bearing at position 3
a ureido, carboxamido, and sulfonamido function, respectively.
All the synthesized compounds were evaluated in a dual-lucif-
erase assay at a concentration of 2 mM, in order to determine their
ability to lower STAT3 activity. The interesting results led us to
investigate if these compounds were able to directly interact with
STAT3. Therefore, they were submitted to the AlphaScreen-
based assay,13 an in vitro competitive binding test used to identify
compounds able to directly inhibit the binding of SH2-containing
proteins to their correspondent phosphopeptides, the physio-
logical ligands. Quite unexpectedly, only N-[4-(4-chlorophenyl)-
1,2,5-oxadiazol-3-yl]-4-(trifluoromethyl)benzamide (MD77)
proved to be able to significantly interact with the SH2 domain.
In parallel,MD77 was retested in the dual-luciferase assay14 at
a higher concentration (5 mM) and its anti-proliferative activity
was evaluated on a panel of 58 cancer cell lines. Here we report
the biological results, the solid state characterization, and the
modeling and docking studies ofMD77, as a new direct inhibitor
of STAT3.Results and discussion
Biological studies
AlphaScreen-based assay. To investigate the direct binding
properties of several 3,4-disubstituted-1,2,5-oxadiazoles12 to the
SH2 domain we performed the AlphaScreen-based assay,13 as
described in the Experimental section. In particular, besides
STAT3, other SH2-containing proteins, such as STAT1 and
Grb2 (‘‘Growth factor receptor-bound protein 2’’), having a high
degree of sequence homology to STAT3 (78% and 65%, respec-
tively) were tested. MD77 was the only compound with a signif-
icant activity versus STAT3 (72.0% of inhibition at
a concentration of 30 mM). Moreover, it selectively antagonized
the STAT3–SH2 domain with respect to the Grb2–SH2 domain
(72.0% versus 10.5% at 30 mM concentration), although it
exhibited a higher affinity toward the STAT1–SH2 domain
(94.6% versus 72.0% at 30 mM concentration).Fig. 1 Dose–response curves of the inhibition of STAT3, STAT1, and
Grb2 binding to pTyr-containing peptides by compound MD77 as
determined by AlphaScreen-based assay (% of activity versus concen-
tration expressed in logarithmic scale).
This journal is ª The Royal Society of Chemistry 2012Its inhibitory activity proved to be dose-dependent (Fig. 1)
with calculated IC50 values of 17.7 mM for STAT3, 7.2 mM for
STAT1 and higher than 100 mM for Grb2.
Dual-luciferase assay. The STAT3 inhibitory activity ofMD77
was evaluated in a dual-luciferase assay,14 at a higher concen-
tration (5 mM) with respect to the published data (2 mM),12 in
human colorectal carcinoma cells HCT-116, characterized by
uncontrolled expression of STAT3 (see Experimental section).
The results showed thatMD77 exhibits an interesting percentage
of inhibition (20%).Chemistry
MD77 was synthesized following slightly modified literature
methods.12 The synthetic procedure consists of six steps with
most of the yields higher than 90% and only two purifications by
flash chromatography (see ESI†).X-Ray and conformational analysis of MD77
The crystallographic structure of MD77 is represented in Fig. 2.
Bond lengths and angles assume the expected standard values.
The overall conformation of the compound is defined by four
torsional angles: N2–C2–N3–C11 (s1) of118(1), C2–N3–C11–
C5 (s2) of 175(1), N3–C11–C5–C6 (s3) of 150(1) and C2–C1–
C3–C13 (s4) of 22(1). The oxadiazole ring is rotated by 25(1)
and 88(1) with respect to the chlorophenyl- and trifluoromethyl-
phenyl moieties, respectively. The latter two rings are perpen-
dicularly oriented with respect to each other, with a dihedral
angle of 87(1). The analysis of the crystal packing has evidenced
the important role played by the halogen atoms in connecting
adjacent molecules, through Cp–H/F, Cp–H/Cl and C]O/
F type contacts, influencing in this way the molecular confor-
mation. Besides, the oxadiazole ring gives rise, in the crystal, to p
interactions with the chloro-phenyl group of symmetry related
molecules along the b axis, indicating the ability of the compound
to interact through molecular stacking with a biological
counterpart.
The crystallographic structure represents only one of the
accessible molecular conformations. Thus, a complete modeling
study of MD77 was carried out, considering all the degrees ofFig. 2 ORTEP15 view of MD77 and the relative arbitrary atom-
numbering scheme (thermal ellipsoids at 40% probability).
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Chart 1 MD77 conformational degrees of freedom.
Table 1 Relative energies, equilibrium percentages, and significant
torsional angles of the minimum energy conformations of MD77
Erel vacuo
(kcal mol1)
P vacuo
(%)
Erel water/
kcal mol1
P water
(%) s1 () s2 () s3 () s4 ()
A 2.10 1.9 0.00 40.9 22 177 154 43
B 2.49 1.0 0.17 30.6 0 177 158 48
C 0.00 65.0 0.28 25.5 126 174 159 34
D 0.42 32.1 1.53 3.0 110 174 156 45
Fig. 4 Superimposition of the crystal structure of compound MD77
(brown) onto theC (pink) andA (magenta) conformers obtained through
rms fitting of the heavy atoms. Hydrogen atoms are omitted for the sake
of clarity.conformational freedom that correspond to the above defined
torsional angles (Chart 1) and, in particular, the arrangement of
the amidic group with respect to the oxadiazole ring. The
geometry optimizations were performed at the B3LYP/
6-311+G(d,p) level16 and the energy of the optimized confor-
mations was recalculated using a polarizable continuum solvent
model (PCM)17 to take into account the effect of water.
Four minimum energy conformations were located and in
Table 1 their geometrical descriptors (s1–s4) are reported,
together with their gas-phase and water-solvated energies and the
corresponding percentage contributions to the overall pop-
ulation. It is worth pointing out that a mirror image conforma-
tion exists for each described conformation; thus, the number of
conformations accessible to the molecule is double with respect
to those reported.
Conformations A and B are very similar (Fig. 3), as evidenced
by their values of s1, s2, and s3, the only difference being the
orientation of the p-chlorophenyl ring (s4). The same occurs for
the couple C and D. The most stable conformation in water (A)Fig. 3 3D plots of conformations A–D of compound MD77.
594 | Med. Chem. Commun., 2012, 3, 592–599accounts for 40.9% of the overall population and, together with
conformation B, represents 71.5%, the remaining not negligible
28.5% being due to the in vacuo preferred conformationsC andD.
A comparison of conformations A–Dwith the above described
crystal structure ofMD77 shows that it corresponds to C, which
is the most stable conformation in vacuo. In fact, the two struc-
tures are characterized by about the same values of s1–s4 and the
overlay of their heavy atoms produces an almost perfect super-
imposition (Fig. 4) with a rms difference value of 0.191 A. By
contrast, the comparison of the solid state structure with
conformer A gives a rms difference value of 1.067 A. The crystal
structure and conformer A orient their amide function in very
different directions (Fig. 4), as evidenced by the significantly
different values of s1: 118(1) in the crystal versus 22 in A. The
amide function usually represents a key moiety for anchoring
a ligand at the binding site of the protein and the ability ofMD77
to vary the orientation of the amide under different conditions is
worthy of note. The orientation in the crystal is determined by
packing interactions, as the molecules form chains through the
hydrogen bond N3–H3/O2I (I at x, y  1, z), forcing in some
way the molecular bending and favoring the conformation
having the carbonyl oxygen pointing in the opposite side with
respect to the chlorophenyl group.
Docking studies
Docking studies were performed onMD77 in order to investigate
its interaction with the SH2 domain. In particular, considering
the STAT3–MD77 complex and the conformational profileFig. 5 Comparison of MD77 (cyan) in the docking pose with the
pTyr-705 (red) of the second subunit in the STAT3 dimer.
This journal is ª The Royal Society of Chemistry 2012
Fig. 7 Main interactions between compound 1 and STAT3. The
hydrogen bonds are shown as dotted lines.of the ligand, the best scored pose showed that the ligand
assumes the most stable conformation A. The binding mode of
MD77 is comparable to that of phosphorylated Tyr-705, because
it involves the same pocket in which pTyr-705 is inserted when
two subunits are assembled in the dimer. The phenyloxadiazole
moiety ofMD77, colored in cyan, occupies the same pocket (not
shown) of pTyr-705, colored in red (Fig. 5).
This pocket is placed on the protein surface and is surrounded
by hydrophilic and polar amino acids to better interact with the
negatively charged side chain of the phosphorylated tyrosine,
mimed by the phenyloxadiazole moiety in the STAT3–MD77
complex.
As shown in Fig. 6, the favored conformation A of MD77
establishes many hydrogen bond interactions within the binding
pocket. In detail, they involve the trifluoromethyl group of the
aromatic ring and the guanidine moiety of Arg-595 by three
hydrogen bonds, the oxygen of the amidic group and the amine
of side chain of Lys-591 by one hydrogen bond, the oxygen and
the nitrogen atoms of the oxadiazole ring and the guanidine
group of Arg-609 by two hydrogen bonds and finally the chlorine
atom of the aromatic ring with one amidic hydrogen of the Gln-
635 side chain.
Despite the presence of three aromatic rings in MD77, p–p
interactions were not found in its complex with the macromol-
ecule, due to the absence of aromatic amino acids in the binding
pocket. Analyzing the other MD77 complexes obtained by
docking, it was possible to identify a pose in which the ligand
assumes a conformation referable to the couple C–D, but its
interaction energy is worse than all calculated complexes and the
binding mode is much different if compared to the most stable
conformation shown above. In particular, the p-tri-
fluoromethylphenyl group is partially inserted in the pTyr-705
pocket while, in the best complex, this pocket is occupied by the
oxadiazole ring. In this complex, the oxadiazole ring does not
mime the phosphate and stabilizes the complex throughFig. 6 Main interactions between MD77 and STAT3. The hydrogen
bonds are shown as dotted lines.
This journal is ª The Royal Society of Chemistry 2012hydrogen bonds with Gln-635 and Lys-626 (see ESI†). Finally,
one of the poses of MD77 corresponds to the mirror image of
conformation A. It presents a different binding mode in which
the pTyr-705 pocket is not occupied, losing the interaction with
Arg-609, but keeping the weak hydrogen bonds between Arg-595
and the trifluoromethyl group.
It should be noted that the sulfonamido bioisoster (1) of
MD77, which was found inactive both in the AlphaScreen and in
the dual-luciferase assays, has a different conformational
behavior with respect to our lead compound. In fact, none of the
localized conformations of 1 shows a relative arrangement of the
aromatic groups similar to that displayed in the four geometries
ofMD77 (see ESI†). Thus, the identification of its binding mode
through docking calculations seemed to be important to clarify
the essential features for an efficient interaction with STAT3
(Fig. 7).
Considering the STAT3-compound 1 complex, the pose and
interacting conformation of the ligand are much different from
those shown by MD77. In particular, compound 1 is unable to
occupy the pTyr-705 pocket and the oxadiazole ring interacts
with Arg-595 instead of Arg-609, which is the key residue
involved in the MD77 complex and in the formation of the salt
bridge with the phosphate group when the protein dimerizes.
Despite the different binding mode, the compound 1 complex is
stabilized by an extended network of hydrogen bonds, shown in
Fig. 7. In the docked conformation of compound 1 the two
benzene rings are perpendicular, the angle between them (89)
being significantly higher than the corresponding value (28)
found for MD77 in the best score pose.
Anti-proliferative assay
In order to verify the anti-proliferative activity of compound
MD77, cell proliferation assays were performed by NCI
(Bethesda, USA) under the Developmental Therapeutic Program
(DTP) to determine its effect on tumor cells growth. MD77 wasMed. Chem. Commun., 2012, 3, 592–599 | 595
Fig. 8 Dose–response curves showing the percentage growth inhibition of compoundMD77 in panel/cell lines (data obtained fromNCI in vitro disease
oriented tumor cell screen).
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exposed to a panel of 58 human tumor cell lines, derived from
9 cancer cell types, and it was firstly tested at a single dose of
10 mM18 (see Experimental section).
Since it exhibited a significant growth inhibition value, it was
subjected to a complete analysis at five different doses for
48 hours. The data are expressed as dose–response parameters
GI50, TGI and LD50 referred toMD77 molar concentration that
produces 50% of growth inhibition, total growth inhibition and
50% of cytotoxicity, respectively (see ESI†). In these assays
MD77 exhibited a good profile of inhibitory activity on cell
proliferation, with GI50 values ranging from 6.75  106 M
(renal cancer, TK10) to 5.46  107 M (leukemia, HL60TB), and
showing TGI values lower than 1.00  104 M in most of the cell
lines (the dose–response parameters expressed as mean graph are
reported in the ESI†).
The dose–response curves showing the activity of MD77 on
the panel/cell lines are represented in Fig. 8. As expected, MD77
inhibits the growth of the cell lines which are known to over-
express STAT3 (for instance HCT116, DU145, and MDA-MB-
231), although several cell lines, such as HL60TB (leukemia cells)
and HOP-92 (non-small cells lung cancer), are the most sensitive.
Conclusions and future perspectives
The ability to target the STAT3–SH2 domain of a series of
oxadiazole derivatives was evaluated in order to identify new,
direct inhibitors. One compound (MD77) proved to be able to
significantly interact with the SH2 domain: in the AlphaScreen
binding assay, it showed an interesting dose–response profile
with an IC50 value of 17.7 mM. This result highlighted its
potential as a protein–protein interaction inhibitor. In addition,
MD77 exhibited a significant activity (20% inhibition at 5 mM) in
a dual-luciferase assay. To investigate the conformational
behavior and the binding mode ofMD77, modeling and docking
studies were performed. The latter evidenced that in the best
scored pose of the STAT3–MD77 complex, MD77 assumes the
most stable conformation calculated in water. It should be noted
that the binding mode of MD77 is comparable to that of pTyr-
705, when the latter is involved in the formation of the STAT3
dimer. The computational data were supported by crystallo-
graphic studies. Finally, MD77 displayed a significant growth
inhibitory activity on a number of tumor cell lines. In the light of
these interesting results, MD77 emerged as a lead for the devel-
opment of a new series of derivatives that is actually underway.
Experimental
AlphaScreen-based assay
AlphaScreen is a bead-based nonradioactive assay system for
detecting biomolecular interactions in a microtiter plate format.
Binding of biological partners brings donor and acceptor beads
into close proximity and as a result, a fluorescent signal between
520 and 620 nm is produced. The AlphaScreen-based assays13
were performed in a final reaction volume of 25 mL of the assay
buffer containing 10 mM HEPES–NaOH (pH 7.4), 50 mM
NaCl, 1 mM EDTA (pH 8.0), 0.1% NP-40, and 10 ng mL1 BSA
in a 96-well microtiter plate at 25 C. Phospho-Tyr (pTyr)
peptide probes used in this study were 5-carboxyfluorescein
(FITC)-GpYLPQTV for STAT3, FITC-GpYDKPHVL forThis journal is ª The Royal Society of Chemistry 2012STAT1, and FITC-PSpYVNVQN for Grb2. Firstly, 75 nM of
each SH2-containing protein was incubated with the test
compound for 15 min. Each protein sample was then incubated
for 90 min with 50 nM of its corresponding FITC-pTyr peptide,
and mixed with streptavidin coated donor beads and anti-FITC
acceptor beads simultaneously before detection at 570 nm using
EnVison Xcite (PerkinElmer).Dual-luciferase assay
Cell culture. The cancer cell lines were obtained from Amer-
ican Type Culture Collection. Human breast cancer cell lines
(MDA-MB-468 and MDA-MB-231) and the human colon
cancer cell line (SW620) were maintained in RPMI 1640 (Gibco/
BRL). Another human colon cancer cell line (HCT-116) was
maintained in McCoy’s 5A (Gibco/BRL). All culture media were
supplemented with 10% heat-inactivated fetal bovine serum
(Gibco/BRL). Cell cultures were maintained at 37 C under
a humidified atmosphere of 5% CO2 in an incubator.
Transient transfection and dual-luciferase assays.14 HCT-116
cells were seeded at a density of 10  105 cells in 100 mm2 culture
plate. The cells were co-transfected with pSTAT3-TA-Luc (27 mg
per plate) and an internal control plasmid pRL-TK (9 mg per
plate) containing the Renilla luciferase gene. All plasmids used in
this experiment were purchased from Promega. The transfection
was carried out using TransFectin (Bio-Rad), according to the
manufacturer’s protocol. After 5 h of transfection, the cells were
trypsinized and seeded onto sterilized black bottom 96-well
plates at a density of 1  104 cells per well. On the following day,
cells were treated with test compounds and incubated for 24 h.
Firefly and Renilla luciferase activities were measured using
a dual-light reporter gene assay kit (Promega) on Wallac Victor2
(Perkin-Elmer, Inc., Wellesley, MA). Renilla luciferase activity
was determined to calibrate transfection efficiency and cytotox-
icity of chemicals. Relative STAT3 activity was calculated by
dividing the firefly luciferase activity with Renilla luciferase
activity in each transfection experiment. The values of STAT3
inhibitory activity were the means of 3 experiments and the
maximum deviation from the mean was less than 10%.
Cell proliferation assay. Cells were seeded at a density of 5000
cells per well in 96-well plates in RPMI 1640 orMcCoy’s medium
containing 10% FBS. They were replenished with fresh complete
medium containing either test compound or 0.1% DMSO. After
incubation for 24 or 48 h, the cell proliferation reagent WST-1
(Roche Applied Science) was added to each well. WST-1 for-
mazan was quantitatively measured at 450 nm using an enzyme-
linked immunosorbent assay reader (Bio-Rad).Crystallography
Crystals of MD77 were obtained from an ethanol solution at
room temperature as white platelets. The intensity data were
collected on an Enraf Nonius CAD-4 diffractometer withMoKa
radiation (l ¼ 0.71073 A) at room temperature. The lattice
parameters were determined by least-squares refinements of
25 high angle reflections. Crystal system: monoclinic (Pc), cell
dimensions (A): a ¼ 11.115(3), b ¼ 5.008(3), c ¼ 14.112(5), b ¼Med. Chem. Commun., 2012, 3, 592–599 | 597
92.28(1). Final R indices [I > 2s(I)] R1 ¼ 0.044, wR2 ¼ 0.057 for
1549 independent reflections. The structure was solved by direct
methods19 and the refinement was carried out with SHELX-97.20
All non-H-atoms were refined anisotropically. The amidic H
position was detected in a difference Fourier synthesis and
refined with isotropic thermal factors, while the other hydrogen
atoms were introduced at calculated positions in their described
geometries and allowed to ride on the attached carbon atom with
fixed isotropic thermal parameters (1.2 Ueq. of the parent carbon
atom).†
Conformational analysis
The calculations were carried out using the Gaussian09 program
package.21 The conformational space of compound MD77 was
explored through optimizations at the B3LYP level with the
6-311+G(d,p) basis set.16 Compound 1 was modeled at the same
level as above (B3LYP/6-311+G(2df,p) level for the S atom). All
the degrees of conformational freedom were considered paying
particular attention to the possible arrangements of the amidic
group with respect to the oxadiazole ring. The energy of the
optimized conformations was recalculated in water using
a polarizable continuum model (PCM).17
Molecular docking
The calculations were performed to evaluate the binding affinity
of MD77 and compound 1 with the STAT3–SH2 domain.
STAT3 structure, co-crystallized with a DNA fragment, was
downloaded from the Protein Data Bank22 (PDB ID 1BG123) and
was dimerized applying the transformation matrix as reported in
the PDB file. The model was completed adding the hydrogens in
two steps: (1) to STAT3, applying the algorithm for proteins and
(2) to DNA, applying the algorithm for nucleic acids. In both
cases, we used the features included in the VEGA ZZ package.24
Atom charges (the Gasteiger–Marsili method25) and potentials
(CHARMM 22 for proteins26 and nucleic acids27) were assigned
to the obtained structure. Finally, the model was optimized
through a conjugate gradients minimization (30 000 steps) in
order to reduce the high-energy sterical interactions. In order to
preserve the experimental data, atom constraints were applied to
the protein and the DNA backbones. This step was carried out by
NAMD 2.828 integrated in the VEGA ZZ graphic environment.
Before running GriDock, the grid maps required to evaluate the
docking score were calculated, selecting the atoms included in
a sphere of 12 A radius centered on phosphorylated Tyr-705
(PTR-705 in the PDB file), which is known to play a pivotal role
in the STAT3 dimerization and activation. This phase was carried
out by AutoGrid 4 interfaced to VEGA ZZ. MD77 and
compound 1 were docked by GriDock/AutoDock29 using the
genetic algorithm search and generating 20 possible solutions. All
these complexes were minimized byNAMD (conjugate gradients,
10 000 steps), keeping the atoms fixed outside from the spheroid
defined by a layer of 12 A thickness around the ligand.
Cell proliferation assays
Compound MD77 was sent to the National Cancer Institute
(NCI) in Bethesda, Maryland (USA) and screened in a panel of
58 human tumor cell lines, derived from nine neoplastic cancer598 | Med. Chem. Commun., 2012, 3, 592–599types (leukemia, lung, colon, CNS, melanoma, ovarian, renal,
prostate, and breast cancers) to test its anti-proliferative activity.
The screening was a two-stage process, beginning with the
evaluation of the compounds against 58 human tumor cell lines
at a single dose of 10 mM. These preliminary results are expressed
as percentages of growth inhibition of treated cell lines per panel
when compared to untreated control cells. MD77 exhibited
a significant growth inhibition and thus it was evaluated against
the 58 cell panel at five concentration levels.
Methodology of the anti-proliferative assay. The anti-prolifer-
ative assay was performed according to the US NCI protocol.18
Briefly, the human tumor cancer cell lines of the screening panel
were grown in RPM 1640 medium containing 5% fetal bovine
serum and 2 mM L-glutamine. Cells were inoculated into 96-well
microtiter plates in 100 mL of complete medium at densities
ranging from 5000 to 40 000 cells per well. The microtiter plates
containing the cells were incubated for 24 h at 37 C, 5% CO2,
95% air and 100% relative humidity prior to addition of the
experimental drug. MD77 was solubilized in dimethyl sulfoxide
at 400-fold the desired final maximum test concentration and
stored frozen prior to use. At the time of drug addition, an
aliquot of frozen concentrate was thawed and diluted twice to the
desired final maximum test concentration with a complete
medium containing 50 mg mL1 gentamicin. Additional four-, 10-
fold serial dilutions were made to provide a total of five drug
concentrations plus control. Aliquots of 100 mL of these different
drug dilutions were added to the appropriate microtiter wells
already containing 100 mL of medium, resulting in the required
final drug concentrations.
Following the addition of the compound, the plates were
incubated for an additional 48 h at 37 C, 5% CO2, 95% air, and
100% relative humidity. Cells were fixed by the gentle addition of
50 mL of cold 50% (w/v) trichloroacetic acid (TCA) and incu-
bated for 60 minutes at 4 C. After washing with tap water and
air drying, Sulforhodamine B (SRB) solution (100 mL) at 0.4%
(w/v) in 1% acetic acid was added to each well, and plates were
incubated for 10 minutes at room temperature. After removing
the unbound dye by washing with 1% acetic acid, the bound stain
was subsequently solubilized with 10 mM Trizma base and the
absorbance was measured on a microplate reader.
Dose–response parameters (GI50, TGI, LD50) were calculated
as reported in the NCI protocol.18Acknowledgements
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